Publications by authors named "Efreen Montano-Figueroa"
Understanding factors limiting hematopoietic cell transplantation for acute myeloid leukemia patients in Mexico: a comprehensive analysis.
Ann Hematol
October 2024
Acute myeloid leukemia (AML) is the most frequent indication for allogeneic hematopoietic cell transplantation (alloHCT) worldwide; social and health system barriers limit its access. We performed an observational retrospective analysis in Mexico to analyze factors limiting alloHCT in fit patients with AML. With a median follow-up of 11.
View Article and Find Full Text PDFArticle Synopsis
- Repeated blood transfusions can lead to iron overload, negatively affecting heart function in patients with myelodysplastic syndromes (MDS), and iron chelation therapy like deferasirox may help prevent this damage.
- The TELESTO study found that patients treated with deferasirox had a significantly lower risk of hospitalization for heart failure or worsening heart function compared to those on a placebo.
- Although deferasirox showed benefits, the study noted that most patients were younger with low cardiovascular risk and had no major heart issues, making the identification of those developing heart failure difficult.
Background: Antithymocyte globulin (ATG)-based immunosuppression is standard in front-line treatment for people with severe aplastic anaemia without a histocompatible donor or who are 40 years or older. However, ATG requires in-hospital administration, is associated with infusion-related toxicities and has limited availability worldwide. In this study, we investigated the activity and safety of an ATG-free regimen of eltrombopag with cyclosporin A as a potential treatment for patients with severe aplastic anaemia who might not have access to or cannot tolerate horse-ATG.
View Article and Find Full Text PDFPurpose: Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous malignant lymphoid neoplasm and is the most common subtype of non-Hodgkin lymphoma in adults. More than half of patients with DLBCL can achieve remission with standard R-CHOP regimes; however, approximately 30-40% of patients are still failing this standard therapy, which remains as an important cause of progression and mortality of this disease. It is necessary to have diagnostic and monitoring tools that allow us to improve the accuracy of prognosis in these patients.
View Article and Find Full Text PDFBackground: In Mexico, patients with hematologic malignancies (HMs) are characterized by being at high risk and advanced stages at diagnosis and by having a low cure rate; yet information on their experiences with health care and health-related quality of life (HRQL) is scarce. We aimed to evaluate experiences with health care and HRQL of patients with HMs and the association between these patient-reported measures.
Methods: We conducted a cross-sectional survey in two public oncology hospitals in Mexico City.
Background: Iron chelation therapy (ICT) in patients with lower-risk myelodysplastic syndromes (MDS) has not been evaluated in randomized studies.
Objective: To evaluate event-free survival (EFS) and safety of ICT in iron-overloaded patients with low- or intermediate-1-risk MDS.
Design: Multicenter, randomized, double-blind, placebo-controlled trial (TELESTO).
Background: In the past decades, long-term survival outcomes for younger patients with acute myeloid leukemia (AML) have improved. Nonetheless, developing nations might be lagging behind, highlighting the need to assess real-world outcomes in such regions.
Methods: We performed a multicenter retrospective study, which included patients with AML diagnosed between January 2013 and December 2017 from 13 centers in Mexico.
Background: The incidence of acute leukemia (AL) has increased. Its prognosis is variable and depends on several baseline characteristics with a highly heterogeneous presentation. In Mexico, large-scale descriptive studies have not yet been published; the objective of this study was to analyze the initial basic characteristics of patients diagnosed with AL in our population.
View Article and Find Full Text PDF[Comparison of the Hyper-CVAD with an institutional regimen for the treatment of acute lymphoblastic leukemia in adults in a hospital of Mexico].
Rev Peru Med Exp Salud Publica
December 2016
Article Synopsis
- A retrospective study assessed the mortality and toxicity of the Hyper-CVAD protocol as a first-line treatment for acute lymphoblastic leukemia in patients under 40, comparing it to the HGMLAL07 regimen.
- Results showed that the Hyper-CVAD regimen had lower complete remission rates (67.7% vs. 81.9%) and survival rates at one year (40% vs. 62%) and two years (18% vs. 34%).
- The study suggests that due to its high cost and toxicity, Hyper-CVAD should primarily be used for patients with relapsed or refractory leukemia.
Objective: to compare the frequency of acute leukemia in two periods of study in a reference Hospital at Mexico City.
Methods: it was an observational study. There were registered 250 cases with the morphology diagnostic criterion of acute leukemia.